logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
I

Iwona Ługowska

Maria Sklodowska-Curie National Research Institute of Oncology
H指数:33
被引数:8,060

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02

曲妥珠单抗德鲁替康在HER2表达型胆道或胰腺肿瘤患者中的疗效与安全性：DESTINY-PanTumor02研究的亚组分析

ESMO Open
IF8.3
2026-07-300
OA
D.-Y. Oh; I. Ługowska; D. Stroyakovskiy; K.H. Jung; O. Dumas; K. Penkov; A. Dechaphunkul; A. Oaknin; S.T. Kim; N. Starling; B. Chewaskulyong; C. Charonpongsuntorn; D. Doroshow; S.-Y. Hsiao; Y.-P. Hung; L. Jung; N. Kuptsova-Clarkson; F. Michelini; S. Puvvada; F. Meric-Bernstam
A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium

代表PCM4EU联盟，对欧洲联盟个性化癌症医学的现有格局进行全面评估。

ESMO Open
IF8.3
2025-11-060
OAAI
S.F. Haj Mohammad; H. van der Pol; E. Vrdoljak; U. Lassen; K. Ojamaa; K. Jalkanen; L. Verlingue; A. Stenzinger; A. Patócs; G. Curigliano; E. Baltruškevičienė; Å. Helland; H.G. Russnes; I. Ługowska; B. Mainoli; A. Edsjö; E. Lonardi; K. Taskén; H. Gelderblom
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Cancer Research Communications
IF0
2025-11-010
OA
Juric, Dejan; Anderson, Daniel; Dowlati, Afshin; Rodon, Jordi; Lugowska, Iwona; Mandziuk, Slawomir; Song, Yuqin; Woei-A-Jin, Feng Jung Sherida H.; Andre, Marc; Tybor, Joanna Gora; Hernandez-Rivas, Jose-Angel; Kurzrock, Razelle; Lopez-Guillermo, Armando; Schroder, David; Stec, Rafal; Berger, Allison; Chao, Bo; Chudnovsky, Aleksander; Gibbs, John P.; Long, Tao; Stroopinsky, Dina; Dong, Qi; Olszanski, Anthony J.
Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe

探索NGS对肉瘤诊断和治疗的影响：来自欧洲多机构真实世界数据的见解

ESMO Open
IF8.3
2025-09-110
OAAI
A. Kyriazoglou; A. Zając; C. Valverde; A.M. Czarnecka; P. Błoński; C. Romagosa; K.A. Seliga; A. Koulouridi; A. Mala; M. Wągrodzki; T.M. Silva; M. Witczak; I. Ługowska; M. Rosińska; R. Álvarez; M. Aguirre; A. Tysarowski; S. Kokkali; V. Georgoulias; C. Serrano; P. Rutkowski; I. Boukovinas
Sinonasal Sarcomas Management: An International Consensus Statement

鼻腔鼻窦肉瘤的管理：一项国际共识声明

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
IF6.8
2025-09-010
OAAI
Vinciguerra, Alessandro; Caspani, Francesca; Valentini, Marco; Camarda, Anna Maria; Provenzano, Salvatore; Wang, Eric W.; Meco, Cem; Ferrari, Marco; Surda, Pavol; Harrabi, Semi; Campos, Fernando Augusto Batista; Broto, Javier Martin; Guadagnolo, B. Ashleigh; Navarria, Pierina; Hosni, Ali; Hindi, Nadia; Italiano, Antoine; Trifiletti, Daniel M.; Kasper, Bernd; Verillaud, Benjamin; Schreiber, Alberto; Castelnuovo, Paolo; Nicolai, Piero; Dallan, Iacopo; Chacon, Matias; Su, Shirley Y.; Thariat, Juliette; Valverde, Claudia; Lechner, Matt; Blay, Jean Yves; Fiore, Maria Rosaria; Eloy, Jean Anderson; Brahmi, Mehdi; Palmer, James N.; Oliden, Victor Castro; Greto, Daniela; Lugowska, Iwona; Tos, Angelo Paolo Dei; van Zele, Thibaut; Psaltis, Alkis J.; Casali, Paolo Giovanni; Dufresne, Armelle; Sangalli, Claudia; Georgalas, Christos; Orlandi, Ester; Wormald, Peter-John; Herman, Philippe; Carrau, Ricardo; Hanna, Ehab Y.; Licitra, Lisa; Turri-Zanoni, Mario; Battaglia, Paolo
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial

重新定义接受新辅助化疗的高风险软组织肉瘤的放射学反应：ISG-STS 1001随机临床试验的最终结果

ESMO OPEN
IF8.3
2025-03-010
OAAI
Vanzulli, A.; Vigorito, R.; Buonomenna, C.; Palmerini, E.; Quagliuolo, V.; Broto, J. M.; Pousa, A. Lopez; Grignani, G.; Brunello, A.; Blay, J. -y.; Beveridge, R. Diaz; Ferraresi, V.; Lugowska, I.; Pizzamiglio, S.; Verderio, P.; Duroni, V.; Fontana, V.; Donati, D. M.; Palassini, E.; Bianchi, G.; Bertuzzi, A.; Buonadonna, A.; Pasquali, S.; Tos, A. P. Dei; Casali, P. G.; Morosi, C.; Stacchiotti, S.; Gronchi, A.
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

研究总结: 通过招募HER2 IHC状态: DESTINY-PanTumor02的事后分析，曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

ADVANCES IN THERAPY
IF4
2025-03-010
OAAI
Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; Gonzalez-Martin, Antonio; Jung, Kyung Hae; Lugowska, Iwona; Manso, Luis; Manzano, Aranzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗治疗复发和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的2期研究

EBIOMEDICINE
IF10.8
2024-11-011
PRE
Verlingue, Loic; Italiano, Antoine; Prenen, Hans; Alia, Eva Maria Guerra; Tosi, Diego; Perets, Ruth; Lugowska, Iwona; Moiseyenko, Vladimir; Gumus, Mahmut; Arslan, Cagatay; Lindsay, Colin R.; Deva, Sanjeev; Taus, Alvaro; Oaknin, Ana; Rottey, Sylvie; Cicin, Irfan; Goksu, Sema Sezgin; Smolin, Alexey; Rosello-Keranen, Susana; Habigt, Christin; Marbach, Daniel; Boetsch, Christophe; Dejardin, David; Sleiman, Nassim; Evers, Stefan; Richard, Muriel; Ardeshir, Caroline; Charo, Jehad; Kraxner, Anton; Teichgraber, Volker; Keshelava, Nino; Dziadziuszkoz, Rafal
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

通过纳入HER2 IHC状态: DESTINY-PanTumor02的事后分析，曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

ADVANCES IN THERAPY
IF4
2024-09-111
OAAI
Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; Gonzalez-Martin, Antonio; Jung, Kyung Hae; Lugowska, Iwona; Manso, Luis; Manzano, Aranzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
CLINICAL CANCER RESEARCH
IF10.2
2024-05-061
PRE
Prenen, Hans; Deva, Sanjeev; Keam, Bhumsuk; Lindsay, Colin R.; Lugowska, Iwona; Yang, James C.; Longo, Federico; de Miguel, Maria; Ponz-Sarvise, Mariano; Ahn, Myung-Ju; Gumus, Mahmut; Champiat, Stephane; Italiano, Antoine; Salas, Sebastien; Perets, Ruth; Arslan, Cagatay; Cho, Byoung C.; Evers, Stefan; Boetsch, Christophe; Marbach, Daniel; Dejardin, David; Sleiman, Nassim; Ardeshir, Caroline; Richard, Muriel; Charo, Jehad; Kraxner, Anton; Keshelava, Nino; Teichgraeber, Volker; Moreno, Victor
Capivasertib plus cyclindependent kinase 4/6 inhibitor and fulvestrant in hormone receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello292
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Hamilton, Erika; Neven, Patrick; Pistilli, Barbara; Beeram, Muralidhar; Borges, Virginia; Campone, Mario; Guimaraes, Jose Luiz Miranda; Foukakis, Theodoros; Kodahl, Annette Raskov; Lau, Peter; Lim, Elgene; Lugowska, Iwona; Rychlik, Greg; Gresty, Christopher; Miller, Claire; Sommavilla, Roberto; Sudhan, Dhivya; Rugo, Hope
Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Siu, Lillian L.; Gil-Martin, Marta; Cho, Byoung Chul; Perets, Ruth; Hilton, John; Geva, Ravit; Lugowska, Iwona; Gutierrez, Martin; Bonomi, Marcelo; Dziadziuszko, Rafal; Rasco, Drew; Ben-Ami, Eytan; Rodriguez, Cristina P.; Siddiqi, Shabana; Myer, Nicole; Suttner, Leah; Wilson, Douglas; Akala, Ombololaji O.; de Miguel, Maria
Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial

成纤维细胞生长因子受体 (FGFR) 共改变 (co-alt) 景观及其对二期开放标签单臂RAGNAR试验中erdafitinib (erda) 反应的影响

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Loriot, Y.; Pant, S.; Witt, O.; Reardon, D. A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; Lugowska, I.; Carranza, O.; Gutierrez, M.; Winter, H.; Sweiti, H.; Thomas, S.; Gormley, M.; Zhang, J.; Triantos, S.; Schuler, M. H. H.

研究方向

暂未获取到该数据
P
Piotr Rutkowski
H 指数:113论文数:1,764被引数:8.7万
J
Jean‐Yves Blay
H 指数:158论文数:2,395被引数:9.5万
P
Paolo G. Casali
H 指数:114论文数:809被引数:5.1万
A
Angelo Paolo Dei Tos
H 指数:109论文数:914被引数:5.4万
A
Alessandro Gronchi
H 指数:114论文数:1,095被引数:4.4万
G
Giovanni Grignani
H 指数:62论文数:633被引数:1.6万
S
Silvia Stacchiotti
H 指数:86论文数:678被引数:2.5万
T
Tomasz Świtaj
H 指数:24论文数:183被引数:2,041
H
Hans Gelderblom
H 指数:107论文数:1,321被引数:5.3万
I
Ian Judson
H 指数:101论文数:589被引数:4.7万